Fact Meets Function

Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests.

This in vitro and animal model study evaluated the safety profile of nicotinamide mononucleotide (NMN) through acute and 90-day sub-chronic dosing experiments in Wistar rats, along with mutagenicity testing. The research assessed toxicological endpoints including clinical signs, body weight changes, organ weights, blood chemistry, and genetic damage potential to establish safety parameters for NMN exposure. This evidence comes from animal model studies and in vitro mutagenicity assays, which represent preliminary safety data that typically precedes human clinical evaluation.

Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests. Read Post »

Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.

This animal model study investigated whether intranasal administration of GHK peptide could reduce Alzheimer’s disease-related symptoms in 5xFAD transgenic mice, which exhibit amyloid pathology and cognitive decline. The researchers found that GHK peptide treatment attenuated both behavioral deficits and neuropathological features associated with Alzheimer’s disease in these mice. This is an animal model study and represents preclinical evidence that would require human clinical validation before any therapeutic applications could be considered.

Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Read Post »

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

Researchers investigated liposomes as delivery vehicles for GHK-Cu tripeptide to improve its cosmetic application potential through in vitro studies. The research evaluated how liposome formulations could enhance the stability and penetration of GHK-Cu, a copper-containing peptide used in skincare products. This was an in vitro study examining formulation properties rather than human or animal testing.

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Read Post »

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.

Researchers developed a double-network hydrogel designed to deliver KPV (a tripeptide derived from α-melanocyte-stimulating hormone) to the colon in an animal model of inflammatory bowel disease, demonstrating that the hydrogel improved markers of mucosal barrier function and reduced inflammation in inflamed colon tissue. The hydrogel formulation was engineered to provide sustained KPV release and enhanced adhesion to the intestinal mucosa compared to free KPV alone. **Evidence level: Animal model**

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Read Post »

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.

This animal model study evaluated a self-cross-linked hydrogel delivery system combining cysteamine-grafted γ-polyglutamic acid with the tripeptide KPV in rats with TNBS-induced ulcerative colitis. The hydrogel formulation demonstrated improved stability of the KPV tripeptide and showed alleviating effects on colitis markers in the rat model. This represents preclinical research requiring further development before clinical translation.

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. Read Post »

Scroll to Top